In Photos: GCC Marks the International Day Against Drug Abuse, Illicit Trafficking
During the celebration of the International Day Against Drug Abuse and the Gulf Anti-Drug Week, Albudaiwi addressed attendees, including representatives from the Ministries of Interior and relevant officials from GCC member states. He remarked, 'This occasion embodies the commitment of the GCC member states to continue collective and joint Gulf action.'
A Unified Strategy for Drug Control
Albudaiwi highlighted the Gulf Strategy for Combating Drugs (2025 – 2028) as a comprehensive framework. He explained, 'This strategy is based on key pillars, including reducing the supply and demand for drugs.' The strategy aims to dry up sources of drugs while promoting alternative development and enhancing the Gulf legislative system.
He added, 'Combating drugs is a collective responsibility that requires integrated action, sustained effort, and close cooperation.' This approach involves collaboration between governments, societies, and individuals to effectively address drug-related issues.
Albudaiwi underscored the vital role of families and society in drug prevention. He stated, 'They constitute the first line of defense against drugs through conscious upbringing, open dialogue, and continuous care.' Schools, media, religious leaders, and civil society institutions also play crucial roles in spreading awareness.
He further emphasized, 'The family has a significant and valuable role in providing emotional and social support.' This support creates a stable environment that boosts the self-confidence of recovering individuals and encourages them to rebuild their lives.
Supporting Recovery and Reintegration
The Secretary General affirmed the importance of integrating recovering addicts into society. He noted, 'The GCC states have been keen to establish hospitals, centres, and institutions dedicated to this matter.' These facilities provide treatment and rehabilitation programs, ensuring active participation in society.
Albudaiwi expressed pride in the cooperation with strategic partners across GCC member states, saying, 'We are keen to bolster these partnerships to ensure coordination and integration at the regional and international levels.'
This collaboration aims to build safe, drug-free societies that protect future generations from the dangers of drug abuse.
Short link :
Post Views: 16
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Argaam
3 days ago
- Argaam
Saudi German Health OKs resignation of nominations and remuneration committee Chairman
Middle East Healthcare Co.'s (Saudi German Health) board of directors approved the resignation of Mohammed Moemena, an independent board member and Chairman of the nominations and remuneration committee. The resignation, submitted on July 2, was due to differences in opinion, perspectives, and a lack of alignment in vision and aspirations, the company said in a statement to Tadawul. The resignation became effective as of Aug. 3. In addition, Saudi German Health appointed Muhammad bin Siddiq as Chairman of the nominations and remuneration committee as of Aug. 3 to complete the current committee term, which is set to end on Sep. 16, 2026. Muhammad bin Siddiq holds a bachelor's degree in business administration from King Abdulaziz University and has over 40 years of experience in management across both listed and private companies. He previously served as a board member, Chairman of the nominations and remuneration committee, and a member of the audit committee at Zahr Al Burtuqal Co. (Orange Bed & Bath). Moreover, the board appointed Ghazi Ahmed Hasanain as an independent member to fill the vacant seat on the board as of today, Aug. 4. He will serve for the remainder of the current board term ending Sept. 16, 2026. Ghazi has more than 40 years of experience in management, engineering, higher education, consulting, and the healthcare sector. He holds a PhD in civil engineering from the University of Missouri-Rolla in the US and held academic and leadership roles at several institutions, including King Abdulaziz University, King Fahd University of Petroleum and Minerals, and King Abdullah University of Science and Technology (KAUST). The board's approval of the appointments is provisional and will be presented at the upcoming general assembly meeting for confirmation, the statement said.
Al Arabiya
28-07-2025
- Al Arabiya
Sarepta will resume gene therapy shipments after fda review of recent patient death
Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients following a brief pause requested by regulators. The Food and Drug Administration said it recommended lifting the hold for young patients with Duchennes muscular dystrophy who are still able to walk. Regulators had requested the pause after the deaths of two older teenagers who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy. Company shares surged more than 16 percent after the announcement to 13.86 in afterhours trading. The jump is the latest in a series of drastic stock movements triggered by changing fortunes for the company's best-selling product. Elevidys is the first gene therapy approved in the US for Duchennes muscular dystrophy–the fatal muscle-wasting disease that affects boys and young men resulting in early death. It received accelerated approval in 2023 for a narrow range of young patients and was expanded last year for use in older patients including those who can no longer walk. The FDA decision Monday significantly improves Elevidys' sales outlook in the near-term, Jefferies analyst Andrew Tsai told investors in a note after the announcement. 'The street will feel relieved about the situation suggesting meaningful stock upside potential.' Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver injury–a known side effect of the treatment. The FDA then requested a pause in shipments of the drug after the death of a third patient taking a different Sarepta therapy. FDA officials have suggested the company will need to provide new study data on safety to resume Elevidys' use in older patients. 'The FDA will continue to work with the sponsor regarding non-ambulatory patients which remains subject to a voluntary hold following two deaths,' FDA said in its statement.
Argaam
27-07-2025
- Argaam
SPIMACO launches oncology, high-potent drug plant
Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) inaugurated its oncology and high potent drugs plant at a total value of SAR 272 million. In a statement to Tadawul today, July 27, SPIMACO said the plant boasts an annual production capacity exceeding 275 million therapeutic units. Incorporating the latest technologies, the new facility adopts the highest international standards in pharmaceutical manufacturing, ensuring operational efficiency, personnel safety, and environmental sustainability. As all technical, regulatory, and operational requirements were completed, the plant will produce the first commercial batches this month, SPIMACO stated.
